Abstract: The present invention discloses tricyclic compounds of formula (I) or salt thereof and their process for synthesis. Further, the present invention relates to the use of these novel tricyclic compounds of formula (I) or salt thereof as insect repellents.

Abstract: An environmentally beneficial process for the production of fuels and chemicals employs carbon dioxide from a natural source or from an artificial chemical source that would otherwise be discharged into the environment. The carbon dioxide is converted to formic acid and the formic acid is then non-biologically converted to fuels and/or chemicals without the intermediate process of hydrogenating the formic acid to methanol or reacting the formic acid with ammonia to form formamide. In the present process, formic acid is converted to one of seven primary feedstocks: formaldehyde, acrylic acid, methane, ethylene, propylene, syngas, and C5-C7 carbohydrates. The formaldehyde, acrylic acid, methane, ethylene, propylene, syngas and/or short chain carbohydrates can either be used directly, or can be converted into a wealth of other products.

Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.

Abstract: The present invention concerns compounds of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein one dotted line represents a carbon-carbon single or double bond and the others a carbon-carbon single bond; each R, independently from each other, represents a hydrogen atom or a methyl or ethyl group provided that at least one of said R groups represents a methyl or ethyl group; and R1 represents a methyl or ethyl group; and their use in perfumery to impart odor notes of the woody type having cedar, ambery, patchouli and/or rooty aspect.

Abstract: The present invention relates to a process for the enantioselective preparation of 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ((1S,4R)-9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide of formula Ib.

Abstract: The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor.

Abstract: The invention relates to a compound of general formula (I) shown hereafter: as well as a composition comprising at least said compound of general formula (I), and its uses in perfumery.

Abstract: The present invention provides a novel 11-step enantioselective approach to the natural product hyperforin, which enables access to a wide variety of hyperforin analogs. The present invention also provides pharmaceutical compositions comprising inventive hyperforin analogs. Hyperforin analogs synthesized using the present synthetic method are envisioned useful in the treatment of various conditions, including, but not limited to, depression and conditions characterized by depression, inflammatory skin conditions, diabetes, asthma, chronic obstructive pulmonary disease (COPD), kidney disorders, and ischemic brain damage.

Abstract: Enantioenriched compositions of liphagal and its derivatives and precursors include more than 50 mol % of a first enantiomer based on the total amount of a first and a second enantiomer. A method of making an enantioenriched composition includes catalytic enantioselective alkylation, ring expansion, and intramolecular aryne cyclization.

Abstract: The present invention relates to methods of initiating a reaction represented by scheme (1), wherein Q is optionally substituted aryl or optionally substituted heteroaryl; X is halogen or a sulphonate; P is an organic radical; R is hydrogen or an organic radical; wherein the catalyst comprises copper and a ligand; comprising providing the compound of formula III in liquid form prior to contacting the compound of formula III with the catalyst.

Abstract: A modified dimethylnaphthalene formaldehyde resin obtained by modifying a polyfunctional dimethylnaphthalene formaldehyde resin having a constituent unit represented by the following general formula [1] in a molecule thereof with at least one member selected from the group consisting of a phenol represented by the following general formula [2], a naphthol represented by the following general formula [3] and a naphthol represented by the following general formula [4] provided that at least any of the naphthol represented by the general formula [3] or the naphthol represented by the general formula [4] must be included.

Abstract: The invention relates to a process for the preparation of 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide.

Abstract: This invention relates to the drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor. The invention also relates to above compounds to treat tumors and other diseases with FIG. 1. These drugs, derivatives and analogs are generated by the modification of the parent or fragment structures and formation of pharmaceutically acceptable salts, complex salts or prodrug. The drugs, derivatives and analogs as described are administered alone or together with at least one known anti-tumor and immune chemotherapeutic agent including treatment of viral, bacterial and fungal diseases, neurological diseases, endocrine system diseases, and immune system diseases.

Abstract: Enantioenriched compositions of liphagal and its derivatives and precursors include more than 50 mol % of a first enantiomer based on the total amount of a first and a second enantiomer. A method of making an enantioenriched composition includes catalytic enantioselective alkylation, ring expansion, and intramolecular aryne cyclization.

Abstract: This invention provides a method of producing cyathin A3 in a culture of Cyathus helenae. It employs added bacteria to stimulate production of cyathin A3.

Abstract: The invention relates to a process for the preparation of 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity.

Abstract: This invention provides a method of producing cyathin A3 in a culture of Cyathus helenae. It employs added bacteria to stimulate production of cyathin A3.

Abstract: The present invention relates to methods of initiating a reaction represented by scheme (1), wherein Q is optionally substituted aryl or optionally substituted heteroaryl; X is halogen or a sulphonate; P is an organic radical; R is hydrogen or an organic radical; wherein the catalyst comprises copper and a ligand; comprising providing the compound of formula III in liquid form prior to contacting the compound of formula III with the catalyst.

Abstract: The invention provides a process for the preparation of 2-substituted-derivatives of estrone and estradiol comprising i) the preparation of a compound of general formula (II) by reacting a compound of general formula (I) in one or more steps to a compound of general formula II wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond. ii) aromatization of the compound of general formula II to a compound of general formula III wherein R1 and R2 have the above defined meanings; and iii) optionally, reduction of the compound of general formula III to a compound of general formula IV wherein R1 and R2 have the above defined meanings. Furthermore the invention provides several novel compounds, which can be intermediates in the above process, and processes to prepare these novel compounds.

Abstract: Novel terpenes and macrocycles are activators of TGR5 and can be used for the prevention and/or treatment of Diabetes Type 2, obesity, neuropathy and/or nephropathy.

Abstract: Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.

Abstract: It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which can be treated, prevented or ameliorated by activation PPAR which contain humulones, isohumulones or lupulones or pharmaceutically acceptable salts or solvates thereof.

Abstract: The present invention relates to the use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug, notably a cardioprotective or hepatoprotective drug.

Abstract: The present invention provides compounds of the general formula I: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I.

Abstract: A compound having the structure of the formula (genus of compound 1 excluding Tashironin or Debenzoyltashironin) wherein, R1 is H or Bz when no more than three of R8, R9, R10 and R11 are H, or R1 is Bn, (C1-C4) alkyl, or CF3; R2 is H, (C1-C4) alkyl, halide, OC(O)(C1-C4)alkyl, OC(O)Ph, or OCF3; R3 is p-toluene sulfonyloxy, methane sulfonyloxy, C(O)(C1-C4)alkyl, or OC(O)(C1-C4)alkyl, bond ? is a single bond, and bond ? is a double bond or R3 is O, bond ? is a double bond and bond ? is a single bond; R4 is H, I, Br, Cl, Si(CH3)3, (C1-C4)alkyl, or OCF3; R5 is OH, OSi(CH3)3, O(C1-C4) alkyl, or OCF3, and bond ? is a single bond, or R5 is O and bond ? is a double bond; R6 is H, (C1-C4) alkyl, or CF3; R7 is H, OH, (C1-C4)alkyl, CH2OBn, CH2O(C1-C4)alkyl, CH2OH, halide, CH2OCF3 or OCF3 and bond ? is a single bond, or R7 is CH2 and bond ? is a double bond; R8, R9, and R10 are each independently H, (C1-C4)alkyl, halide, OH, or OCF3; R11 is H, (C1-C4)alkyl, halide, OH, or OCF3 and bond ? is a single bond; R12 is H, (

Abstract: The use of novel methanoazulenofuran and methanoazulenone compounds for use as fragrance chemicals, suitable for use incorporated in a wide variety of products such as perfumes, colognes and personal care products having a structure wherein R is ?O, X is selected from the group consisting of H, CH3, C2H5, and CH2CH?CH2; or wherein R forms a fused ring with the ring carbon at the X position, X is absent; and Y and Z are selected from the group consisting of H and CH3.

Abstract: Cyclohexane is reacted with hydrogen peroxide in the presence of nitric acid which is used as a catalyst in a suitable solvent for the production of trimeric cyclohexane peroxide.

Abstract: The present invention provides compounds of general formula I or II: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I or II, intermediates and processes useful for preparing compounds of formula I or II, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I or II.

Abstract: 1-Deoxybaccatin III, 1-deoxytaxol and 1-deoxy taxol analogs and method for the preparation thereof.

Abstract: A method of preparing a polycyclic compound containing a ketone functionality comprising: reacting a mixture comprising a catalyst, a reactant compound and an amount of water greater than or equal to 3 weight percent (wt %) based on the weight of the reactant compound; wherein said catalyst comprises nickel and base and said reactant compound comprises at least two fused rings, A and B wherein ring A is a saturated ring or ring system having 5 to 7 cyclic carbons and substituted with a hydroxyl functionality and ring B is a non-aromatic unsaturated ring having 5 to 6 cyclic carbons; and converting the hydroxyl functionality of ring A to a ketone functionality and non-aromatic unsaturated ring B to a saturated ring.

Abstract: The present invention provides compounds of general formula I or II: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I or II, intermediates and processes useful for preparing compounds of formula I or II, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I or II.

Abstract: The present invention provides a method of synthesizing compounds of formula (I) or (II): wherein R1 is hydrogen, R′ is (C1-C4)alkyl and X is a hydroxyl protecting group.

Abstract: Improved, safe process for the purification of ketones obtained by ozonolysis and subsequent reduction of the corresponding terpenes, in which, after the ozonolysis and reduction of acyclic mono-, bi- or tricyclic terpenes with ozonizable double bonds, converting the resulting corresponding crude ketone into a high-purity ketone by means of steam distillation at atmospheric pressure or at reduced pressure, extraction of the steam distillate and subsequent distillation.

Abstract: An adamantanemethanol derivative of the invention is represented by the following formula (1), wherein Ra is a hydrogen atom or a hydrocarbon group; Rb is a hydrocarbon group having a carbon atom, to which carbon atom at least one hydrogen atom is bonded, at a bonding site with the adjacent carbon atom; Rc, Rd and Re are each a hydrogen atom, a hydroxyl group which may be protected by a protective group or the like; provided that a hydroxyl group protected by a protective group or the like is bonded to at least one carbon atom constituting the adamantane skeleton when Ra is a hydrogen atom or a methyl group and Rb is a methyl group; and at least one substituent, in addition to the HO—C(Ra)(Rb)— group indicated in the formula (1), is bonded to the adamantane ring when one of Ra and Rb is a methyl group and the other is an ethyl group.

Abstract: This invention relates generally to non-steroidal estrogen-receptor (ER) antagonists that are useful as therapeutics in the treatment of advanced stage breast cancer. More particularly, this invention relates to the cloning and heterologous expression of genes encoding ER antagonists. This invention also relates to the use of such expression to overproduce the ER antagonist and analogs thereof.

Abstract: By treating the reactant of 3,4-ditrimethylsilyloxytricyclo[4.2.1.02.5]nona-3,7-diene and binaphthol monoether-tin tetrachloride complex, optically active acyloin is produced. Using the optically active acyloin compound as a starting material, optically active oxydicyclopentadiene useful as several kinds of intermediates can be obtained efficiently.

Abstract: The invention relates to the use of .alpha.-hydroxyketoalkyl derivatives as light protection filters for cosmetic or pharmaceutical products, the .alpha.-hydroxyketoalkyl group being linked, if appropriate via a spacer, to a chromophoric group which has an absorption maximum in a wavelength range of between 280 and 400 nm and has a conjugated .pi.-electron system of at least 8 .pi.-electrons, and to new .alpha.-hydroxyalkyl derivatives, processes for their preparation and pharmaceutical and cosmetic formulations comprising these derivatives as light protection substances.

Abstract: A process for preparing substituted 4-methylidenecinnamic acid derivatives of Formula (I). ##STR1## The variables are defined herein. The compounds of Formula (I) can be used, for example, as UV absorbers.

Abstract: The invention relates to ketotricyclo[5.2.1.0]decane derivatives of the formula I ##STR1## wherein Phe is a phenyl group which is unsubstituted or substituted by 1 to 5 hydroxyl, alkyl or alkoxy groups having 1 to 10 C atoms,and their preparation and use as UV filters, in particular in cosmetic or pharmaceutical formulations.

Abstract: The invention relates to the use of .alpha.-hydroxyketoalkyl derivatives as light protection filters for cosmetic or pharmaceutical products, the .alpha.-hydroxyketoalkyl group being linked, if appropriate via a spacer, to a chromophoric group which has an absorption maximum in a wavelength range of between 280 and 400 nm and has a conjugated .pi.-electron system of at least 8 .pi.-electrons, and to new .alpha.-hydroxyalkyl derivatives, processes for their preparation and pharmaceutical and cosmetic formulations comprising these derivatives as light protection substances.

Abstract: A method of inhibiting viruses in which a virus is contacted with diamondoid alcohol, ketone, ketone derivative, adamantyl amino acid, quaternary salt or combinations thereof which have antiviral properties. These diamondoid derivatives are shown to have antiviral activity against HIV.

Abstract: (1RS,5RS)-5-Methyl-exo-tricyclo[6.2.1.0.sup.2,7 ]undecan-4-one, as well as the compositions which contain a preponderant amount of this compound together with its isomer (1RS,5SR)-5-methyl-exo-tricyclo[6.2.1.0.sup.2,7 ]undecan-4-one, are useful as perfuming ingredients for the preparation of perfuming compositions and perfumed articles, to which they impart aromatic, thujonic and herbaceous odors.

Abstract: The present invention provides special epoxy derivative (1), cyclohexanone derivative (2), cyclohexenone derivative (3) and 3-substituted cyclohexenone derivative (4) which are useful as intermediates for synthesizing physiologically active materials, and a method for stereoselectively introducing substituted groups. Further, the present invention provides a method for synthesizing optically active compounds, such as optically active carvone via these intermediates.

Abstract: The present invention relates to optically active cyclohexene diol derivatives and optically active cyclohexenone derivatives, and a process for production of these compounds in which a special cyclohexene diol of a starting material is reacted by selectively positioning transesterification in the presence of lipase to obtain an optically active cyclohexene diol derivative and then an optically active cyclohexenone derivative represented by the following formula: ##STR1## According to the present invention, optically active cyclohexene diol derivatives and optically active cyclohexenone derivatives, which are intermediates for synthesizing physiologically active materials, can be obtained efficiently.

Abstract: Bleaching compositions comprising an inorganic peroxygen compound and a bicyclic or tricyclic diketone as an activator for the peroxygen compound. The composition preferably comprises about 1 to about 75% of the peroxygen bleaching compound and about 1 to about 75% of the bicyclic or tricyclic diketone bleaching compound activator. The conventional additives such as surfactants, antifoaming agents, fabric softeners, stablizers, inorganic builder salts, buffers, enzymes and the like may be present as indicated. The compositions can be formulated as dry concentrated, aqueous solutions, aqueous solutions containing non-aqueous solvents, etc. The compositions are environmentally safe, effective as bleaching agents from below room temperature to higher temperatures, biodegradable and otherwise highly desirable.

Abstract: Neuroactive benz[e]indene compounds ##STR1## are prepared by a total synthesis from the following three starting materials ##STR2##

Abstract: The compounds of formula ##STR1## wherein symbol X designates a C.dbd.O (Ia) or C(CH.sub.3)--OC(O)CH.sub.3 (Ib) group and the dotted line indicates the location of a single or double bond in formula (Ia) and of a double bond in formula (Ib), are characterised by useful odor notes of the aromatic, fruity, even amber type and can as a result be advantageously used as active perfuming ingredients.

Abstract: Novel tricyclic steriod analogs are disclosed which are 1H-benz[e]indene dodecahydro compounds that are useful for enhancing GABA-induced chloride currents at the GABA receptor/chloride ionophore complex and can be represented by the following structural formulas: ##STR1## wherein R.sub.1 =H or C.sub.1 -C.sub.4 alkyl or fluoroalkyl;R.sub.2 =H or C.sub.1 -C.sub.4 alkyl or fluoroalkyl, in which R.sub.1 and R.sub.2 can be the same or different;R.sub.3 =H or CH.sub.3 ;R.sub.4 =H or CH.sub.3, in which R.sub.3 and R.sub.4 can be the same or different;R.sub.5 =H;R.sub.6 =H;R.sub.5,R.sub.6 =.dbd.O(carbonyl);R.sub.7 =H;R.sub.8 =a hydrogen bond accepting group.R.sub.7,R.sub.8 =.dbd.O(carbonyl); andR'=an ester group.

Abstract: A antiandrogenic compositions comprising an anti-androgenically effective amount of at least one compound of the formula ##STR1## wherein R is alkyl of 1 to 4 carbon atoms, R.sub.1 is alkyl of 1 to 2 carbon atoms, R.sub.2 is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms optionally interrupted with a heteroatom, alkenyl and alkynyl of 2 to 8 carbon atoms optionally interrupted with a heteroatom, formyl and acyl of an organic carboxylic acid of 2 to 18 carbon atoms, R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and alkenyl and alkynyl of 2 to 4 carbon atoms, R.sub.4 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, the dotted lines indicate optional presence of a double bond between the 4(5) and 5a(6) carbons and the wavy line indicates that R.sub.4 may be in the .alpha.- or .beta.